[HTML][HTML] iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting
KM Snyder, KJ Dixon, Z Davis, M Hosking… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Antibody therapies can direct natural killer (NK) cells to tumor cells, tumor-
associated cells, and suppressive immune cells to mediate antibody-dependent cell …
associated cells, and suppressive immune cells to mediate antibody-dependent cell …
[HTML][HTML] Examination of IgG Fc receptor CD16A and CD64 expression by canine leukocytes and their ADCC activity in engineered NK cells
R Hullsiek, Y Li, KM Snyder, S Wang, D Di… - Frontiers in …, 2022 - frontiersin.org
Human natural killer (NK) cells can target tumor cells in an antigen-specific manner by the
recognition of cell bound antibodies. This process induces antibody-dependent cell …
recognition of cell bound antibodies. This process induces antibody-dependent cell …
iNK-CD64/16A cells: a promising approach for ADCC?
B Walcheck, J Wu - Expert opinion on biological therapy, 2019 - Taylor & Francis
Introduction: ADCC by natural killer (NK) cells is a key mechanism for several clinically
successful tumor-targeting therapeutic antibodies. Most patients, however, have limited …
successful tumor-targeting therapeutic antibodies. Most patients, however, have limited …
[HTML][HTML] Engineering anti-tumor monoclonal antibodies and Fc receptors to enhance ADCC by human NK cells
Simple Summary Human natural killer (NK) cells can be targeted to tumor antigens by their
IgG Fc receptors that interact with the Fc regions of antibodies that recognize surface …
IgG Fc receptors that interact with the Fc regions of antibodies that recognize surface …
[HTML][HTML] Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic …
Y Chen, F You, L Jiang, J Li, X Zhu, Y Bao, X Sun… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Natural killer (NK) cells play a pivotal role in monoclonal antibody-mediated immunotherapy
through the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. NK-92MI is …
through the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. NK-92MI is …
Anti-CD20 therapy acts via FcγRIIIA to diminish responsiveness of human natural killer cells
C Capuano, M Romanelli, C Pighi, G Cimino, A Rago… - Cancer Research, 2015 - AACR
Natural killer (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by
aggregating FcγRIIIA/CD16, contributing significantly to the therapeutic effect of CD20 …
aggregating FcγRIIIA/CD16, contributing significantly to the therapeutic effect of CD20 …
[HTML][HTML] Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy
KV Woan, H Kim, R Bjordahl, ZB Davis, S Gaidarova… - Cell Stem Cell, 2021 - cell.com
Select subsets of immune effector cells have the greatest propensity to mediate antitumor
responses. However, procuring these subsets is challenging, and cell-based …
responses. However, procuring these subsets is challenging, and cell-based …
[HTML][HTML] Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs
C Capuano, C Pighi, S Battella, D De Federicis… - Cancers, 2021 - mdpi.com
Simple Summary Natural Killer (NK) cells play a major role in cancer immunotherapy based
on tumor-targeting mAbs. NK cell-mediated tumor cell killing and cytokine secretion are …
on tumor-targeting mAbs. NK cell-mediated tumor cell killing and cytokine secretion are …
[HTML][HTML] Off-the-shelf, multiplexed-engineered iPSC-derived NK cells mediate potent multi-antigen targeting of B-cell malignancies with reduced cytotoxicity against …
F Cichocki, JP Goodridge, R Bjordahl, S Gaidarova… - Blood, 2021 - Elsevier
Treatments for B-cell malignancies have improved over the past several decades with
clinical application of the CD20-specific antibody rituximab and chimeric antigen receptor …
clinical application of the CD20-specific antibody rituximab and chimeric antigen receptor …
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
S Battella, MC Cox, A Santoni… - Journal of Leucocyte …, 2016 - academic.oup.com
Tumor-targeting mAb are widely used in the treatment of a variety of solid and hematopoietic
tumors and represent the first immunotherapeutic approach successfully arrived to the clinic …
tumors and represent the first immunotherapeutic approach successfully arrived to the clinic …